Interferon Beta-1b
Antiviral, Systemic · Immunomodulator
Indications
Patients with a single demyelinating event with an active inflammatory process severe enough to require IV corticosteroids if alternative diagnosis have been excluded and they are at high risk of developing multiple sclerosis. Relapsing-remitting multiple sclerosis in patients who have had at least 2 attacks in the preceding 2 years. Secondary progressive multiple sclerosis with active disease evidenced by relapses.
Dosage
Adults: Initially 62.5 mcg by SC inj on alternate days increasing slowly over a period of 19 days to 250 microgram on alternate days. Discontinue if no response (e.g. steady progression of disability for 6 mth or treatment with at least 3 courses of ACTH or corticosteroids in 1 yr). Reassess after 2 yr. Children: Under 12 yr, not recommended.
Administration
Withdraw 1 mL of reconstitution solution from the vial into a sterile syringe fitted with a 27-gauge needle and inject the solution SC, sites for self-injection include arms, abdomen, hips and thighs. Reconstitution: To reconstitute solution, inject 1.2 mL of diluent provided. Do not shake. Reconstituted solution provides 0.25 mg/mL. Use product within 3 hours of reconstitution. Stability: Store at room temperature of 25°C; excursions permitted to 15°C to 30°C.
Adverse Effects
Inj site reactions, flu-like symptoms, necrosis, leucopenia, anaemia, thrombocytopenia, altered blood chemistry, depression, hypertonia, hypertension, GI upset, alopecia, urticaria, pruritus, rash, myalgia. Rarely, lymphadenopathy, thyroid dysfunction, convulsions, confusion, anxiety, emotional lability, cardiomyopathy (discontinue), tachycardia, palpitations, bronchospasm, dyspnoea, pancreatitis, hepatitis, skin discolouration, sweats, menstrual disorders, suicide attempts, anaphylaxis, malaise, chest pain, weight loss, arthralgia, increased LFTs, hypothyroidism, nephrotic syndrome, hepatic injury.
Risk Factor (Pregnancy/Lactation)
Pregnancy: Risk cannot be ruled out. Lactation: Contraindicated or not recommended. Contraindications: History of severe depression or suicidal tendencies, decompensated liver disease, uncontrolled epilepsy. Ensure adequate contraception. Precautions: Treatment must be initiated under the supervision of a clinician experienced in the disease. History of seizures or depression, cardiac disorders, monoclonal gammopathy, myelosuppression, anaemia, thrombocytopenia, renal impairment (monitor renal function). Monitor patient for symptoms of depression, suicidal ideation, hypersensitivity reactions, fever and infection associated with neutropenia; consider withdrawal if occur. Monitor haematology and liver enzymes prior to and regularly during therapy; consider withdrawal with significant changes. Thyroid dysfunction; monitor thyroid function regularly.
Interactions
Drugs metabolised by liver enzymes, other immunomodulators (except corticosteroids and ACTH), drugs affecting haematopoietic system.
Advice to Patient
Use as directed. Follow exact instructions for injection and syringe disposal. Inform prescriber immediately if you feel depressed or any suicidal thoughts occur to you. Contact prescriber if there is unusual bruising or bleeding, constant stomach upset, muscle pain, tremors, unusual fatigue, swelling of ankles/hands/feet, palpitations, chest pain, change in vision, pain/redness/swelling/burning at injection site, broken skin or black-blue discolouration around the injection site. Take sufficient amount of fluids (2-3 litres per day) to maintain hydration, unless restricted by the prescriber.
Pharmacokinetics
Limited data due to small doses used. Half-life elimination: 8 mins-4.3 hrs. Time to peak, serum: 1-8 hrs.
Brands with this active ingredient
Compiled by Healify Pharmacy from published drug references. How we compile it →
Always consult a pharmacist or doctor.